EC Number | Application | Comment | Organism |
---|---|---|---|
3.4.21.B10 | medicine | active hK6 is present in ovarian cancer ascites fluid, provides a rationale for the development of novel therapeutic strategies | Homo sapiens |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.4.21.B10 | additional information | activity of hK6 can be suppressed by ca. 60% by monoclonal antibody E24 | Homo sapiens |
EC Number | KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|---|
3.4.21.B10 | 0.23 | - |
Pro-Phe-Arg-7-amido-4-methylcoumarin | purified hK6 | Homo sapiens | |
3.4.21.B10 | 0.3 | - |
Phe-Ser-Arg-7-amido-4-methylcoumarin | purified hK6 | Homo sapiens | |
3.4.21.B10 | 0.36 | - |
Val-Pro-Arg-7-amido-4-methylcoumarin | purified hK6 | Homo sapiens |
EC Number | Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|---|
3.4.21.B10 | 30000 | - |
purified hK6, Western blot analysis | Homo sapiens |
3.4.21.B41 | 30000 | - |
SDS-PAGE | Homo sapiens |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.21.B10 | Homo sapiens | - |
- |
- |
3.4.21.B41 | Homo sapiens | O43240 | - |
- |
EC Number | Purification (Comment) | Organism |
---|---|---|
3.4.21.B10 | hK6 purified on immunoaffinity columns, followed by reverse-phase high performance liquid chromatography, to homogeneity | Homo sapiens |
3.4.21.B41 | reverse-phase high-performance liquid chromatography and immunoaffinity chromatography | Homo sapiens |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.4.21.B10 | additional information | ovarian cancer ascites fluid from ovarian cancer patients during therapeutic drainage. hK6 and hK10 concentrations are positively correlated in ovarian cancer ascites fluid, majority of hK6 present in the free (uncomplexed) form | Homo sapiens | - |
3.4.21.B41 | ascites fluid | all K10 present in ovarian cancer ascites fluids are in the uncomplexed, zymogen form and have no detectable enzymatic activity | Homo sapiens | - |
3.4.21.B41 | ovary cancer cell | - |
Homo sapiens | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.21.B10 | additional information | hK6 shows weak trypsin-like enzymatic activity, does not cleave Val-Leu-Lys-7-amido-4-methylcoumarin, Glu-Lys-Lys-7-amido-4-methylcoumarin and Ala-Ala-Pro-Phe-7-amido-4-methylcoumarin | Homo sapiens | ? | - |
? | |
3.4.21.B10 | Phe-Ser-Arg-7-amido-4-methylcoumarin | purified hK6 | Homo sapiens | Phe-Ser-Arg + 7-amino-4-methylcoumarin | - |
? | |
3.4.21.B10 | Pro-Phe-Arg-7-amido-4-methylcoumarin | purified hK6 | Homo sapiens | Pro-Phe-Arg + 7-amino-4-methylcoumarin | - |
? | |
3.4.21.B10 | Val-Pro-Arg-7-amido-4-methylcoumarin | purified hK6 | Homo sapiens | Val-Pro-Arg + 7-amino-4-methylcoumarin | - |
? | |
3.4.21.B41 | additional information | kallikrein 10 from asites fluid does not cleave L-Val-Pro-Arg-7-amido-4-methylcoumarin, L-Phe-Ser-Arg-7-amido-4-methylcoumarin, L-Pro-Phe-Arg-7-amido-4-methylcoumarin, L-Val-Leu-Lys-7-amido-4-methylcoumarin, L-Glu-Lys-Lys-7-amido-4-methylcoumarin, and L-Ala-Ala-Pro-Phe-7-amido-4-methylcoumarin | Homo sapiens | ? | - |
? |
EC Number | Subunits | Comment | Organism |
---|---|---|---|
3.4.21.B10 | ? | x * 30000, SDS-PAGE, purified hK6 | Homo sapiens |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.4.21.B10 | hK6 | - |
Homo sapiens |
3.4.21.B10 | kallikrein 6 | - |
Homo sapiens |
3.4.21.B41 | kallikrein 10 | - |
Homo sapiens |
EC Number | Turnover Number Minimum [1/s] | Turnover Number Maximum [1/s] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|---|
3.4.21.B10 | 0.0003 | - |
Pro-Phe-Arg-7-amido-4-methylcoumarin | purified hK6 | Homo sapiens | |
3.4.21.B10 | 0.00083 | - |
Phe-Ser-Arg-7-amido-4-methylcoumarin | purified hK6 | Homo sapiens | |
3.4.21.B10 | 0.0013 | - |
Val-Pro-Arg-7-amido-4-methylcoumarin | purified hK6 | Homo sapiens |